Minimal Hepatic Encephalopathy is Associated with Increased Cerebral Vascular Resistance. A Transcranial Doppler Ultrasound Study.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
25 10 2019
Historique:
received: 25 02 2019
accepted: 09 10 2019
entrez: 27 10 2019
pubmed: 28 10 2019
medline: 30 10 2020
Statut: epublish

Résumé

Minimal hepatic encephalopathy (MHE) is a subclinical complication of liver cirrhosis with a relevant social impact. Thus, there is urgent need to implement easy to use diagnostic tools for the early identification of affected patients. The aim of this study was to investigate cerebral blood flow, systemic hemodynamics as well as endothelial function of cirrhotic patients with MHE, and to verify their change after treatment with rifaximin. Fifty cirrhotic patients with or without MHE and an equal number of healthy controls underwent transcranial Doppler ultrasound (TCD), abdominal Doppler ultrasound (US), and measurement of flow mediated dilation (FMD). In cirrhotic patients diagnosed with MHE receiving rifaximin, the tests were repeated at the end of treatment. Middle (MCA) and posterior (PCA) cerebral artery resistive (RI) and pulsatility (PI) indices were higher in cirrhotic patients than controls, as well as renal and splenic artery RI. Conversely, FMD was reduced. MCA-RI and PI were even higher in cirrhotic patients with MHE compared to those without; a MCA-RI cut-off of 0.65 showed an accuracy of 74% in discriminating the presence of MHE, with 65% sensitivity and 76% specificity. Rifaximin treatment showed no efficacy in the modulation of cerebral vascular flow. In conclusion, cirrhotic patients with MHE have significantly increased cerebral vascular resistances that are not improved by rifaximin treatment. MCA-RI measurement has a good accuracy for the diagnosis of MHE and can be useful for the early identification of this harmful complication of liver cirrhosis.

Identifiants

pubmed: 31653939
doi: 10.1038/s41598-019-51867-6
pii: 10.1038/s41598-019-51867-6
pmc: PMC6814853
doi:

Substances chimiques

Ammonia 7664-41-7

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

15373

Références

Hepatology. 2020 Feb;71(2):611-626
pubmed: 31220352
Metab Brain Dis. 2001 Jun;16(1-2):67-78
pubmed: 11726090
Hepatology. 1994 Jun;19(6):1437-44
pubmed: 8188174
Hepatology. 2014 Aug;60(2):715-35
pubmed: 25042402
Aliment Pharmacol Ther. 2007 Feb;25 Suppl 1:3-9
pubmed: 17295846
Hepatology. 1998 Jul;28(1):45-9
pubmed: 9657095
J Neurol Neurosurg Psychiatry. 1986 Mar;49(3):302-9
pubmed: 3083051
Expert Rev Gastroenterol Hepatol. 2018 Jul;12(7):641-656
pubmed: 29806487
Dig Dis Sci. 2010 Aug;55(8):2381-90
pubmed: 20508990
Aging Clin Exp Res. 2002 Apr;14(2):117-31
pubmed: 12092785
Hepatology. 1998 Jul;28(1):39-44
pubmed: 9657094
Am J Gastroenterol. 2013 Jan;108(1):75-82
pubmed: 23147518
J Hepatol. 1997 Dec;27(6):986-92
pubmed: 9453423
Hepatology. 1985 Sep-Oct;5(5):831-6
pubmed: 4029894
Liver Int. 2008 Dec;28(10):1396-401
pubmed: 18673435
Dig Liver Dis. 2016 Aug;48(8):904-8
pubmed: 27160697
Hepatology. 1999 Jun;29(6):1662-7
pubmed: 10347105
Gastroenterology. 2009 Mar;136(3):863-71
pubmed: 19041869
Metab Brain Dis. 2001 Jun;16(1-2):37-41
pubmed: 11726087
J Gastroenterol Hepatol. 2001 Aug;16(8):890-7
pubmed: 11555103
Hepatology. 2006 Feb;43(2 Suppl 1):S121-31
pubmed: 16447289
Liver Int. 2015 Feb;35(2):344-52
pubmed: 24690075
Liver Transpl. 2018 Dec;24(12):1673-1679
pubmed: 30207422
World J Gastroenterol. 2017 Jul 7;23(25):4491-4499
pubmed: 28740337
Radiographics. 2009 Nov;29(7):2081-98
pubmed: 19926763
Neurochem Int. 2012 Jun;60(7):697-706
pubmed: 21989389
J Neuroimaging. 2007 Jan;17(1):11-8
pubmed: 17238867
Hepatology. 1995 Feb;21(2):428-33
pubmed: 7843716
Eur J Radiol. 2013 Nov;82(11):1981-8
pubmed: 23849331
Hepatology. 2013 Jan;57(1):258-65
pubmed: 22886493
Hepatology. 2004 Jul;40(1):73-9
pubmed: 15239088
Turk J Gastroenterol. 2016 May;27(3):264-7
pubmed: 27210783
Hepatology. 2017 Feb;65(2):592-603
pubmed: 27775818
J Hepatol. 2014 Sep;61(3):642-59
pubmed: 25015420

Auteurs

Francesca Romana Ponziani (FR)

Internal Medicine, Gastroenterology and Hepatology, Fondazione Policlinico Agostino Gemelli IRCCS, Rome, Italy. francesca.ponziani@gmail.com.

Barbara Funaro (B)

Internal Medicine, Gastroenterology and Hepatology, Fondazione Policlinico Agostino Gemelli IRCCS, Rome, Italy.

Andrea Lupascu (A)

Internal Medicine, Fondazione Policlinico Agostino Gemelli IRCCS, Rome, Italy.

Maria Elena Ainora (ME)

Internal Medicine, Gastroenterology and Hepatology, Fondazione Policlinico Agostino Gemelli IRCCS, Rome, Italy.

Matteo Garcovich (M)

Internal Medicine, Gastroenterology and Hepatology, Fondazione Policlinico Agostino Gemelli IRCCS, Rome, Italy.

Gianluigi Caracciolo (G)

Internal Medicine, Gastroenterology and Hepatology, Fondazione Policlinico Agostino Gemelli IRCCS, Rome, Italy.

Alessandro Quadarella (A)

Internal Medicine, Gastroenterology and Hepatology, Fondazione Policlinico Agostino Gemelli IRCCS, Rome, Italy.

Antonio Nesci (A)

Internal Medicine, Fondazione Policlinico Agostino Gemelli IRCCS, Rome, Italy.

Laura Riccardi (L)

Internal Medicine, Gastroenterology and Hepatology, Fondazione Policlinico Agostino Gemelli IRCCS, Rome, Italy.

Antonio Gasbarrini (A)

Internal Medicine, Gastroenterology and Hepatology, Fondazione Policlinico Agostino Gemelli IRCCS, Rome, Italy.

Maurizio Pompili (M)

Internal Medicine, Gastroenterology and Hepatology, Fondazione Policlinico Agostino Gemelli IRCCS, Rome, Italy.

Maria Assunta Zocco (MA)

Internal Medicine, Gastroenterology and Hepatology, Fondazione Policlinico Agostino Gemelli IRCCS, Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH